8Mon
Thanks for the analysis. $NOVO B is one of the top performers in my portfolio and will certainly remain a long-term component. Even if the competition never sleeps, it is a top positioned company in a growing market.
•
22
•
@Since1887 I agree. In 2018, Novo Nordisk showed that it can always assert itself with innovative products. However, you have to be prepared for a cooling of the share price, unless Novo Nordisk once again comes up with news that nobody expects.
••
8Mon
@investorsapiens You're right about that. That can also be a good thing for the run, because a lot is already priced in.
••